Bose Kochupurakkal
Senior Scientist
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (6)
Purpose: We explored the efficacy of PARP inhibition combined with sapacitabine, an orally bioavailable prodrug of the deoxycytidine analog 2′-C-cyano-2′-deoxy-1-β-D-arabino-pentofuranosylcytosine, in patients with germline BRCA1/2– mutated HER2-negative metastatic breast cancer. Patients and Methods: In this phase Ib investigator-sponsored study of sapacitabine and olaparib, patients who were PARP inhibitor–naïve were enrolled. The primary objective was determination of the recommended phase 2 dose (RP2D) of sapacitabine with olaparib. Archival samples were subjected to IHC for biomarkers of homologous recombination repair (HRR) deficiency and replication stress. Serial blood samples were collected for ctDNA analysis. Results: Ten patients (3 BRCA1 and 7 BRCA2 ) were enrolled. The RP2D was not determined due to hematologic toxicities. The objective response rate (ORR) was 50% (95% confidence interval, 18.7%–81.3%), with median progression-free survival (mPFS) of 9.7 months (95% confidence interval, 8.02–not estimable). Three patients had clinical benefit greater than 15 months, including two who remained on trial for more than 40 months. Tumors from responding patients demonstrated HRR deficiency and/or replication stress by IHC. At progression, ctDNA from two patients had evidence of BRCA reversion mutations associated with a microhomology-mediated end-joining signature, and three patients had acquired putative nonreversion mechanisms of resistance. Conclusions: Sapacitabine with olaparib produces high rates of hematologic toxicity. However, the ORR of 50%, mPFS of 9.7 months, and durability of response in some patients suggest possible combinatorial benefit. Further exploration of olaparib with different sapacitabine schedules or substitution of a PARP1-selective inhibitor to potentially decrease hematologic toxicity is warranted.
Year:
2026
Figure S4. H-score of pre- and on-treatment biopsy stained with anti-SLFN11 antibody for each patient is shown. Patients from cohort 4 was not included in the analysis. Patients from T4 was not included in this analysis.
Year:
2025
Figure S3: (A) Kaplan-Meier plot for PFS vs time on study where patients were stratified based on p53 status of the tumor. The p53 status was available for 15 patients in the study. Patients from T4 was not included in this analysis.
Year:
2025
Figure S1: (A) Study schema. Patients were recruited into one of four cohorts based on NGS or IHC. Patients received twice-per week infusions of berzosertib at the recommended phase 2 dose. Paired biopsies were collected for cohorts 1 to 3 for translational studies. Six patients were allowed per cohort; however, patients could be replaced if paired biopsies were unsuccessful. *For cohort T3, gene alterations included: germline BRCA1/2 mutations, other homologous repair (HR) alterations (e.g., somatic BRCA1/2, BARD1, BRIP1, CDK12, CHEK2, FANCA, FANCC, FANCE, FANCF, FANCM, MRE11A, NBN, PALB2, RAD51B, RAD51C and RAD51D), MYC amplification, FBXW7 truncating or missense mutations, CCNE1 amplification, ARID1A mutations. (B) Kaplan-Meier plot showing Progression free survival of patients in each cohort
Year:
2025
Purpose: Preclinical studies have identified molecular correlates of sensitivity to ATR inhibition. This translational study was designed to test the ATR inhibitor berzosertib in patients with advanced solid tumors carrying alterations in ATRX , ataxia-telangiectasia–mutated (ATM) , genes conferring replication stress (RS), or SDH . Patients and Methods: Patients were recruited to four cohorts: T1: ATRX -mutant leiomyosarcoma; T2: ATM- mutant solid tumors; T3: solid tumors with mutations in RS-associated genes; and T4: SDH -deficient gastrointestinal stromal tumors (GIST). Patients were treated with berzosertib 240 mg/m 2 intravenously twice per week. Pretreatment and on-treatment biopsies were obtained in cohorts T1 to T3. Results: Patients with SDH -mutant GIST had the longest median progression-free survival (PFS; 229 days) with stable disease as the best response. Patients in the other cohorts experienced progressive disease within 4 months. There was no significant difference in PFS comparing outcomes in patients with/without mutations in ATM or RS genes. Decreased pS345-CHK1 levels in on-treatment biopsies indicated target engagement by berzosertib and were accompanied by substantial increases in levels of DNA damage (γ-H2AX) and RS (pKAP1) markers in a subset of patients. However, these biomarker changes did not translate to clinical benefit. In contrast, in cohorts T1 to T3, increased expression of SLFN11 on treatment correlated with clinical benefit (HR = 0.045; 95% confidence interval, 0.005–0.400). Conclusions: Across cohorts, only patients with SDH -mutant GIST experienced prolonged disease control. Despite evidence of target engagement, patients enrolled to all other cohorts had short PFS, suggesting rapid adaptation to ATR inhibitor monotherapy. Among these patients, those with tumors expressing SLFN11 during berzosertib exposure derived the most clinical benefit.
Year:
2025
Given that radium-223 is a radiopharmaceutical that induces DNA damage, and olaparib is a PARP inhibitor that interferes with DNA repair mechanisms, we hypothesized their synergy in metastatic castration-resistant prostate cancer (mCRPC). We sought to demonstrate the safety and efficacy of olaparib + radium-223. We conducted a multicenter phase I 3+3 dose escalation study of olaparib with fixed dose radium-223 in patients with mCRPC with bone metastases. The primary objective was to establish the RP2D of olaparib, with secondary objectives of safety, PSA response, alkaline phosphatase response, radiographic progression-free survival (rPFS), overall survival, and efficacy by homologous recombination repair (HRR) gene status. Twelve patients were enrolled; all patients received a prior androgen receptor signaling inhibitor (ARSI; 100%) and 3 patients (25%) prior docetaxel. Dose-limiting toxicities (DLT) included cytopenias, fatigue, and nausea. No DLTs were seen in the observation period however delayed toxicities guided the RP2D. The RP2D of olaparib was 200 mg orally twice daily with radium-223. The most common treatment-related adverse events were fatigue (92%) and anemia (58%). The rPFS at 6 months was 58% (95% confidence interval, 27%–80%). Nine patients were evaluable for HRR gene status; 1 had a BRCA2 alteration (rPFS 11.8 months) and 1 had a CDK12 alteration (rPFS 3.1 months). Olaparib can be safely combined with radium-223 at the RP2D 200 mg orally twice daily with fixed dose radium-223. Early clinical benefit was observed and will be investigated in a phase II study.
Year:
2025
Collaborators (16)
Khanh Do
Assistant Professor of Medicine
Dana-Farber Cancer Institute
Eliezer Van Allen
Professor
Harvard University
Biren Saraiya
Assistant Professor of Medicine
Rutgers Cancer Institute of New Jersey
Rahul Parikh
Associate Professor of Medicine
University of Kansas Medical Center
Judy Garber
Chief, Division of Cancer Genetics and Prevention
Dana-Farber Cancer Institute
Lee Zou
Duke University
Neal Lindeman
Vice Chair, Molecular Pathology and Laboratory Medicine
Weill Cornell Medicine
Alan D'Andrea
Director, Center for DNA Damage and Repair
Dana-Farber Cancer Institute
Brittany Bychkovsky
Assistant Professor of Medicine
Dana-Farber Cancer Institute
Huy Nguyen
Dana-Farber Cancer Institute
Adam Olson
Assistant Professor
UPMC Hillman Cancer Center
S. Percy Ivy
Associate Chief
National Cancer Institute
Filipa Lynce
Dana-Farber Cancer Institute
Colin Weekes
Associate Professor
Massachusetts General Hospital
Rana R. McKay
University of California, San Diego
Mamta Parikh
Associate Professor
University of California Davis Comprehensive Cancer Center
Make your next move.
Prepare your application
Review drafts before you send them.